Final Results from the First-in-Human Phase 1/2 Study of Modakafusp Alfa, an Immune-Targeting Attenuated Cytokine, in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
2022; Elsevier BV; Volume: 140; Issue: Supplement 1 Linguagem: Inglês
10.1182/blood-2022-162253
ISSN1528-0020
AutoresDan T. Vogl, Shebli Atrash, Sarah A. Holstein, Omar Nadeem, Don M. Benson, Kaveri Suryanarayan, Yuyin Liu, Sabrina Collins, Xavier Parot, Jonathan L. Kaufman,
Tópico(s)Peptidase Inhibition and Analysis
Referência(s)